New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics

MC Lobo, TS Whitehurst, SJ Kaar, OD Howes - … & Biobehavioral Reviews, 2022 - Elsevier
Schizophrenia is associated with substantial unmet needs, highlighting the necessity for
new treatments. This narrative review compares the pharmacology, clinical trial data and …

[HTML][HTML] Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies

T Ali, M Sisay, M Tariku, AN Mekuria, A Desalew - PloS one, 2021 - journals.plos.org
Background Antipsychotic agents are the basis for the pharmacological management of
acute and chronic schizophrenia, bipolar disorders, mood disorders with psychotic feature …

[HTML][HTML] Efficacy and safety of esmethadone (REL-1017) in patients with major depressive disorder and inadequate response to standard antidepressants: a phase 3 …

M Fava, SM Stahl, L Pani, S De Martin… - The Journal of …, 2024 - psychiatrist.com
Objective: To test esmethadone (REL-1017) as adjunctive treatment in patients with major
depressive disorder (MDD) and inadequate response to standard antidepressants. Methods …

[HTML][HTML] Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature

GM Giordano, F Brando, P Pezzella… - Frontiers in …, 2022 - frontiersin.org
The integration of pharmacotherapy with psychosocial interventions has an important role to
play in the improvement of functional outcome of subjects with schizophrenia (SCZ), in all …

Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: a Delphi expert consensus study

S Galderisi, M De Hert, S Del Prato, A Fagiolini… - European …, 2021 - cambridge.org
BackgroundPatients with schizophrenia spectrum disorders (SSD) have worse physical
health and reduced life expectancy compared to the general population. In 2009, the …

Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the “ …

P Monteleone, G Cascino, AM Monteleone… - Progress in Neuro …, 2021 - Elsevier
First generation antipsychotics (FGAs) are more likely to induce extrapyramidal side-effects
(EPS) than second generation antipsychotics (SGAs), and EPS have been shown …

Major depression, sleep, hostility and body mass index are associated with impaired quality of life in schizophrenia. Results from the FACE-SZ cohort.

G Fond, T Korchia, PLS de Verville, O Godin… - Journal of Affective …, 2020 - Elsevier
Abstract Background Impaired Quality of life (QoL) in schizophrenia has been mostly
associated with psychotic and mood symptomatology, insight and functioning so far. Aims …

[HTML][HTML] The Impact of Antipsychotic Treatment on Neurological Soft Signs in Patients with Predominantly Negative Symptoms of Schizophrenia

C Petrescu, IR Papacocea, C Vilciu, OA Mihalache… - Biomedicines, 2022 - mdpi.com
Schizophrenia is a complex and incompletely elucidated pathology that affects sensorimotor
function and also produces numerous therapeutic challenges. The aims of this cross …

[HTML][HTML] Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms

S Zhang, Y Ma - World Journal of Psychiatry, 2022 - ncbi.nlm.nih.gov
Parkinson's disease (PD) is the second most common neurodegenerative disease.
Psychosis is one of the common psychiatric presentations in the natural course of PD. PD …

Relationship between drug-induced movement disorders and psychosis in adults living in precarious housing or homelessness

DD Kim, RM Procyshyn, AA Jones, KM Gicas… - Journal of Psychiatric …, 2024 - Elsevier
Background Studies have reported positive associations between drug-induced movement
disorders (DIMDs) and symptoms of psychosis in patients with schizophrenia. However, it is …